Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Cardax's ZanthoSyn® is No. 1 Seller at GNC Hawaii Stores | |||
By: PR Newswire Association LLC. - 17 Feb 2018 | Back to overview list |
||
HONOLULU, Feb. 17, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that ZanthoSyn® (60 count), the Company's premium astaxanthin dietary supplement for inflammatory health and longevity, was the top selling product in Hawaii GNC stores for the fourth quarter of 2017, based on information provided to Cardax by GNC Holdings, Inc. ("GNC"). The product was first introduced in GNC's Hawaii stores in Q1 2017. "Becoming the top selling, #1 product in GNC Hawaii so quickly is a significant milestone," said Gilbert Shin, Cardax Vice President, Retail Sales and Marketing. "This achievement reflects strong retail engagement by Hawaii GNC store personnel as well as strong product acceptance across a broad range of consumer demographics." "We are very encouraged by the success of ZanthoSyn at GNC in Hawaii," added Cardax CEO David G. Watumull. "Gil and his team have really demonstrated the viability of our sales and marketing strategy in Hawaii and we look forward to implementing this model nationwide." Cardax recently announced that ZanthoSyn® became available at more than 3,000 GNC corporate stores in the U.S. in the fourth quarter of 2017. Cardax plans to drive ZanthoSyn® sales nationally through its two-pronged approach, modeled after Cardax's successful program in Hawaii:
"The sales and marketing strategy that led to ZanthoSyn's Hawaii success and its national availability is a key building block of our goal to become the inflammatory health, anti-aging leader," added George W. Bickerstaff, Cardax Chairman. The Company's relationship with GNC reflects Cardax's mission to develop and commercialize the safest, most effective anti-inflammatory products for health and longevity. Cardax is also developing and commercializing CDX-085, its next generation patented ZanthoSyn® product for more concentrated astaxanthin product applications. CDX-085 was chosen by the National Institutes of Health as a top anti-aging prospect. About Cardax About ZanthoSyn® About Astaxanthin Media and Investors Safe Harbor
View original content with multimedia:http://www.prnewswire.com/news-releases/cardaxs-zanthosyn-is-no-1-seller-at-gnc-hawaii-stores-300600425.html SOURCE Cardax, Inc. |
|||
|
|||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |